These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618 [TBL] [Abstract][Full Text] [Related]
24. Combination effect of cetuximab with radiation in colorectal cancer cells. Shin HK; Kim MS; Lee JK; Lee SS; Ji YH; Kim JI; Jeong JH Tumori; 2010; 96(5):713-20. PubMed ID: 21302618 [TBL] [Abstract][Full Text] [Related]
25. Histone demethylase JMJD1A promotes colorectal cancer growth and metastasis by enhancing Wnt/β-catenin signaling. Peng K; Su G; Ji J; Yang X; Miao M; Mo P; Li M; Xu J; Li W; Yu C J Biol Chem; 2018 Jul; 293(27):10606-10619. PubMed ID: 29802196 [TBL] [Abstract][Full Text] [Related]
26. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance. Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111 [TBL] [Abstract][Full Text] [Related]
27. Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine. Prasad S; Yadav VR; Sung B; Reuter S; Kannappan R; Deorukhkar A; Diagaradjane P; Wei C; Baladandayuthapani V; Krishnan S; Guha S; Aggarwal BB Clin Cancer Res; 2012 Sep; 18(18):4942-53. PubMed ID: 22832932 [TBL] [Abstract][Full Text] [Related]
28. RNF6 promotes colorectal cancer invasion and migration via the Wnt/β-catenin pathway by inhibiting GSK3β activity. Li Q; Wang G; Tao J; Chen W Pathol Res Pract; 2021 Sep; 225():153545. PubMed ID: 34352441 [TBL] [Abstract][Full Text] [Related]
29. CircIFNGR2 enhances proliferation and migration of CRC and induces cetuximab resistance by indirectly targeting KRAS via sponging to MiR-30b. Zhang Q; Zheng Y; Liu J; Tang X; Wang Y; Li X; Li H; Zhou X; Tang S; Tang Y; Wang X; He H; Li T Cell Death Dis; 2023 Jan; 14(1):24. PubMed ID: 36639711 [TBL] [Abstract][Full Text] [Related]
30. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer. Lu H; Zhang H; Weng ML; Zhang J; Jiang N; Cata JP; Ma D; Chen WK; Miao CH J Cell Physiol; 2021 Jun; 236(6):4445-4454. PubMed ID: 33184860 [TBL] [Abstract][Full Text] [Related]
31. FUBP1 promotes colorectal cancer stemness and metastasis via DVL1-mediated activation of Wnt/β-catenin signaling. Yin H; Gao T; Xie J; Huang Z; Zhang X; Yang F; Qi W; Yang Z; Zhou T; Gao G; Yang X Mol Oncol; 2021 Dec; 15(12):3490-3512. PubMed ID: 34288405 [TBL] [Abstract][Full Text] [Related]
32. Ginkgolide C promotes apoptosis and abrogates metastasis of colorectal carcinoma cells by targeting Wnt/β-catenin signaling pathway. Yang MH; Ha IJ; Lee SG; Lee J; Um JY; Ahn KS IUBMB Life; 2021 Oct; 73(10):1222-1234. PubMed ID: 34273236 [TBL] [Abstract][Full Text] [Related]
33. TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer. Tarpgaard LS; Ørum-Madsen MS; Christensen IJ; Nordgaard C; Noer J; Guren TK; Glimelius B; Sorbye H; Ikdahl T; Kure EH; Tveit KM; Nielsen HJ; Pfeiffer P; Brünner N; Moreira JM Oncotarget; 2016 Sep; 7(37):59441-59457. PubMed ID: 27509063 [TBL] [Abstract][Full Text] [Related]
34. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression. Weng WH; Leung WH; Pang YJ; Hsu HH Oncol Rep; 2016 Jan; 35(1):107-16. PubMed ID: 26496897 [TBL] [Abstract][Full Text] [Related]
35. Cytoplasmic SHMT2 drives the progression and metastasis of colorectal cancer by inhibiting β-catenin degradation. Liu C; Wang L; Liu X; Tan Y; Tao L; Xiao Y; Deng P; Wang H; Deng Q; Lin Y; Jie H; Zhang H; Zhang J; Peng Y; Zhang H; Zhou Z; Sun Q; Cen X; Zhao Y Theranostics; 2021; 11(6):2966-2986. PubMed ID: 33456583 [No Abstract] [Full Text] [Related]
36. Thymol Isolated from Zeng Q; Che Y; Zhang Y; Chen M; Guo Q; Zhang W Drug Des Devel Ther; 2020; 14():2535-2547. PubMed ID: 32669835 [TBL] [Abstract][Full Text] [Related]
37. OVOL2, an Inhibitor of WNT Signaling, Reduces Invasive Activities of Human and Mouse Cancer Cells and Is Down-regulated in Human Colorectal Tumors. Ye GD; Sun GB; Jiao P; Chen C; Liu QF; Huang XL; Zhang R; Cai WY; Li SN; Wu JF; Liu YJ; Wu RS; Xie YY; Chan EC; Liou YC; Li BA Gastroenterology; 2016 Mar; 150(3):659-671.e16. PubMed ID: 26619963 [TBL] [Abstract][Full Text] [Related]
38. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status. Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179 [TBL] [Abstract][Full Text] [Related]
39. KY1022, a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway, inhibits development of metastatic colorectal cancer. Cho YH; Cha PH; Kaduwal S; Park JC; Lee SK; Yoon JS; Shin W; Kim H; Ro EJ; Koo KH; Park KS; Han G; Choi KY Oncotarget; 2016 Dec; 7(49):81727-81740. PubMed ID: 27835580 [TBL] [Abstract][Full Text] [Related]
40. Forkhead Box S1 mediates epithelial-mesenchymal transition through the Wnt/β-catenin signaling pathway to regulate colorectal cancer progression. Zhang L; Ren CF; Yang Z; Gong LB; Wang C; Feng M; Guan WX J Transl Med; 2022 Jul; 20(1):327. PubMed ID: 35864528 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]